Quest diagnostics to introduce ki-67 ihc mib-1 pharmdx, the first companion diagnostic for eli lilly and company's verzenio® (abemaciclib), a cdk4/6 inhibitor for certain people with hr+ her2- high risk early breast cancer

Secaucus, n.j., oct. 18, 2021 /prnewswire/ -- quest diagnostics (nyse: dgx), the world's leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the ki-67 ihc mib-1 pharmdx (dako omnis) immunohistochemistry companion diagnostic.
DGX Ratings Summary
DGX Quant Ranking